After receiving funding from the Bill & Melinda Gates Foundation, ProMed Pharma has begun preclinical evaluation of a novel fully resorbable contraceptive implant.
The Plymouth, Minnesota–based company imagines that the contraceptive implants could ultimately find use in low- and middle-income (LMIC) settings.
The novel implant potentially could offer women 18 months of contraception through the long-term release of levonorgestrel, a hormonal type of birth control first patented in 1960.
Get the full story from our sister site, Drug Discovery & Development.